Analyst Expectations for Bristol-Myers Squibb's Future
Portfolio Pulse from Benzinga Insights
Analysts have provided mixed ratings for Bristol-Myers Squibb (NYSE:BMY) in the last quarter, with 2 bullish, 4 indifferent, and 3 somewhat bearish. The average 12-month price target for the company is $67.78, a decrease of 0.57% from the previous average of $68.17.
July 19, 2023 | 6:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Mixed analyst ratings and a slight decrease in the average price target may lead to uncertainty in Bristol-Myers Squibb's stock performance.
The mixed analyst ratings indicate differing opinions on the company's performance, which can lead to uncertainty among investors. The slight decrease in the average price target also suggests a potential downward trend, although it is not significant enough to definitively predict a decrease in stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100